Navigation Links
Neovasc Inc. Reports Second Quarter 2009 Financial Results
Date:8/19/2009 

     - Growing Traction in Specialty Tissue Business Producing Increased
                                 Revenues -
         - Neovasc Reducer(TM) Commercialization Process on Track -

    TSX Venture Exchange: NVC

VANCOUVER, Aug. 19 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), today announced financial results for the three and six months ended June 30, 2009.

"During the second quarter we continued to make significant progress in executing on our strategic initiatives adopted late last year," said Alexei Marko, chief executive officer of Neovasc. "We are especially pleased at the growing traction we are seeing in our tissue business, where our decision to focus on our specialty products and services is beginning to bear fruit, with increases in tissue sales already evident. We were pleased in the second quarter to report significantly lower expenses compared to last year, at the same time that we were able to advance the development of our innovative Neovasc Reducer(TM) device."

Mr. Marko continued, "While holding down costs we have also been able to ramp up our business development activities, and the response to date is very encouraging. On this note, we were delighted that LeMaitre Vascular, one of our key strategic partners, cited our Peripatch product as an important contributor to their second quarter sales growth."

Financial Results

Results for the three and six months ended June 30, 2009 follow. All amounts are in Canadian dollars.

Revenues

Revenues increased 39% year-over-year from $433,061 for the quarter ended June 30, 2008 to $600,324 for the quarter ended June 30, 2009. For the six months ended June 30, 2009, revenues increased 10% to $955,808, up from $866,546 for the six months ended June 30, 2008, primarily reflecting increased revenues from consulting and contract manufacturing services in our tissue products and services b
'/>"/>

SOURCE Neovasc Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Arbor, Mich. Children had half as many ... evening office hours on five or more days a ... at C.S. Mott Children,s Hospital and Johns Hopkins University. ... in The Journal of Pediatrics and will ... "These findings are an important step in understanding where ...
(Date:6/19/2013)... ROCHESTER, Minn. -- Nearly 70 percent of ... and more than half take two, Mayo Clinic ... most commonly prescribed, their study found. Twenty percent ... medications, according to the findings, published online in ... MULTIMEDIA ALERT: For audio and video of Dr. ...
(Date:6/19/2013)... June 19, 2013 North Carolina-based ... organizational changes to advance development of its technologies. ... “To support the advanced development of our product ... to the Company’s management structure and engaged industry ... Company announced that Michael Galiger will serve as ...
(Date:6/19/2013)... Brightree LLC , the leading provider of ... post-acute care industry, has been ranked for the first time ... 100 (HCI 100) list. This prestigious list features the ... of revenue during the last fiscal year. Since 2005, Brightree’s ... and the company has built its organization to more than ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... More than 90% of drugs entering,clinical development fail ... of,effectiveness or adverse side effects not detected in ... pre-clinical tests using stem cell,technologies, potentially saving drug ... Cells: Worldwide Markets for,Transplantation, Cord Blood Banking and ...
... condition associated with pregnancy responds to energy restoration, ... the editor,in today,s USA Today, board-certified cardiologist Stephen T. ... a rare and often,misunderstood form of heart disease. Responding ... twins who developed peripartum cardiomyopathy, an,uncommon and mystifying type ...
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. ... the BioCentury "Future,Leaders in the Biotech Industry" Conference ... New York City on Thursday, March 27, 2008 ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... GlaxoSmithKline (NYSE: GSK ),today reported its ... equivalent to almost 4% of pre-tax profits for ... Donations of albendazole treatments,for the company,s flagship program ... valued at $29 million, bringing the,total number of ...
... of natural compound found in heparin samples , , WEDNESDAY, ... they,ve identified the contaminant found in the blood-thinner heparin, ... and possibly 19 deaths in the United States. , ... sulfate, but U.S. Food and Drug Administration officials could ...
... Profits before ... Patients, ST. ... their side, International Union of Operating,Engineers Local 49 leaders today at a ... off medical coverage to,several thousand Minnesota seniors., "This is a death ...
Cached Medicine News:Health News:Stem Cell Technology Offers Promise of Huge Savings for Drug Developers 2Health News:Metabolic Cardiologist Offers New Hope for Women With Heart Disease 2Health News:GSK Charitable Support Valued at $564 Million in 2007 2Health News:GSK Charitable Support Valued at $564 Million in 2007 3Health News:FDA Identifies Contaminant in Blood-Thinning Drug 2Health News:FDA Identifies Contaminant in Blood-Thinning Drug 3Health News:Park Nicollet to Cut Off Care to Thousands of Minnesota Seniors 2
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
(Date:6/19/2013)... June 19, 2013 DST Health Solutions, LLC ... to health plans, integrated delivery systems, and health care ... Drug Management Service (MDMS) has jumped significantly. ... automate the pricing of medical prescription drug claims, MDMS ... automating their medical drug claims processes. As specialty drug ...
Breaking Medicine Technology:Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5Amerivet Solutions Expands to Manufacture Complex Metal Designs 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3
... 27 ChemoCentryx, Inc., today announced that ... PROTECT-1 Study (the Prospective Randomized Oral Therapy ... (CCX282-B) in patients with moderate-to-severe Crohn,s disease. ... antagonist showed clinical efficacy in a 12-week ...
... NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... specializing in the development, manufacturing, and marketing of branded ... it will report its unaudited financial results for the ... 11, 2010, before the market opens in the United ...
Cached Medicine Technology:ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 2ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 3ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 4ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 5Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: